| Literature DB >> 31568476 |
Andrea-Clemencia Pineda-Peña1,2, Marta Pingarilho1, Guangdi Li3, Bram Vrancken4, Pieter Libin4,5, Perpétua Gomes6,7, Ricardo Jorge Camacho4, Kristof Theys4, Ana Barroso Abecasis1.
Abstract
BACKGROUND: Portugal has one of the most severe HIV-1 epidemics in Western Europe. Two subtypes circulate in parallel since the beginning of the epidemic. Comparing their transmission patterns and its association with transmitted drug resistance (TDR) is important to pinpoint transmission hotspots and to develop evidence-based treatment guidelines.Entities:
Mesh:
Year: 2019 PMID: 31568476 PMCID: PMC6768452 DOI: 10.1371/journal.pone.0218226
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characteristics of the transmission clusters (TCs) in the general cohort and in the cohort with TDR.
| Characteristic | General population | TDR population in TCs | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| B | G | p-value | B | G | p-value | |||||
| n | % | n | % | n | % | n | % | |||
| | 497 | 100 | 333 | 100 | 82 | 100 | 31 | 100 | ||
| Median size (IRQ) | 2 | (2–3) | 2 | (2–3) | NS | 3 | (2–4) | 2 | (2–4) | NS |
| | 221 | 44.5 | 132 | 39.6 | NS | 42 | 51.2 | 15 | 48.4 | NS |
| Median size (IRQ) | 4 | (3–5) | 4 | (3–5) | NS | 4 | (3–6) | 4 | (3–6) | NS |
| | 120 | 24.1 | 47 | 14.1 | 0.0003 | 26 | 31.7 | 4 | 12.9 | NS |
| Median size (IRQ) | 2 | (2–3) | 2 | (2–2) | NS | 2 | (2–3) | 2,5 | (2–3) | NS |
| | 36 | 7.2 | 4 | 1.2 | <0.0001 | 11 | 13.4 | 2 | 6.5 | NS |
| Median size (IRQ) | 3 | (3–4) | 3 | (3–3.25) | NS | 3 | (3–4) | 3 | (-) | |
| | ||||||||||
| | 24 | 29.3 | 7 | 22.6 | NS | |||||
| Median size (IRQ) | - | - | - | - | 3 | (3–4) | 4 | (3–5) | NS | |
| | 7 | 8.5 | 1 | 3.2 | NS | |||||
| Median size (IRQ) | - | - | - | - | 2 | (2–2.5) | 3 | (-) | ||
| | ||||||||||
| Number of cohort and controls | 1636 | 100 | 972 | 100 | 343 | 100 | 100 | 100 | ||
| Number of cohort patients | 1250 | 100 | 726 | 100 | NS | 146 | 100 | 51 | 100 | NS |
| | ||||||||||
| Number of cohort and controls | 1084 | 66.3 | 570 | 58.6 | 0.0001 | 263 | 76.7 | 68 | 68 | NS |
| Number of cohort patients | 828 | 66.2 | 411 | 56.6 | <0.0001 | 99 | 67.8 | 30 | 58.8 | NS |
| | ||||||||||
| Number of cohort and controls | 302 | 18.5 | 99 | 10.2 | <0.0001 | 75 | 21.9 | 10 | 10.0 | 0.0089 |
| Number of cohort patients | 286 | 22.9 | 93 | 12.8 | <0.0001 | 40 | 27.4 | 4 | 7.8 | 0.0225 |
| | ||||||||||
| Number of cohort and controls | 134 | 8.2 | 12 | 1.2 | <0.0001 | 43 | 12.5 | 6 | 6.0 | NS |
| Number of cohort patients | 128 | 10.2 | 12 | 1.7 | <0.0001 | 19 | 13.0 | 1 | 2.0 | N |
| | ||||||||||
| | ||||||||||
| Number of cohort and controls | - | - | - | - | - | 95 | 27.7 | 32 | 32.0 | NS |
| Number of cohort patients | - | - | - | - | - | 72 | 49.3 | 21 | 41.2 | NS |
| | - | - | - | - | - | |||||
| Number or cohort and controls | - | - | - | - | - | 26 | 7.6 | 6 | 6.0 | NS |
| Number of cohort patients | - | - | - | - | - | 26 | 17.8 | 2 | 3.9 | NS |
Abbreviations: IQR: interquartile range, n: sample, NS: No significant, TCs: Transmission clusters TDR: transmitted drug resistance, % percentage.
Fig 1Number of naïve patients in transmission clusters of the PT-naïve cohort vs time of origin (i.e. most recent common ancestor- MRCA) of those TCs.
The number of naive patients included in the TCs is represented in the y-axis while the year of origin is in the x-axis. The type of clusters is presented as pairs (dashed line) and clusters ≥3 (solid line) for B (dark red) and G-like (blue). (A) Time of origin (MRCA) of non-drug resistant TCs in the PT-naïve cohort (B) Time of origin (MRCA) of all TDR TCs in the PT-naïve cohort. Time of introduction of Highly Effective Antiretroviral Therapy (HAART) (1996), time of start of needle and syringe program (NSP) in Portugal (1993), time of increasing number of regimen options (2001) and time of introduction of potent drugs (2007) are marked as grey dotted lines in the x-axis.
Fig 2Prevalence of subtype G in Portuguese originated people during the period of the study (years in the y-axis) when considering the ones who were in transmission clusters (A). The light blue shades are the confidence intervals of the proportion of patients for a period of two years (dark blue line). The first period was excluded given the few numbers of patients but significance did not change. (B) Prevalence (dot) and 95% confidence intervals of the Transmitted drug resistance for subtypes B (red) and G (dark blue) for the PT-naive cohort and for each drug group. Geographical differences were observed for TDR when Lisbon was compared with other regions. Significant differences are shown with an asterisk. Abbreviations: NRTI: Nucleoside reverse transcriptase inhibitors, NNRTI: non-NRTI, PI: Protease inhibitors; TCs: Transmission clusters, vs: versus, %: percentage.